Astria Therapeutics Enters Worldwide Exclusive License Agreement With Ichnos Sciences For An OX40 Portfolio; To Pay Ichnos One-time Upfront License Fee Of $15M, Up To $305M In Milestones
Portfolio Pulse from Benzinga Newsdesk
Astria Therapeutics has entered into an exclusive worldwide license agreement with Ichnos Sciences for an OX40 portfolio. Astria will pay Ichnos a one-time upfront license fee of $15M and up to $305M in milestones. Astria plans to submit an IND application for STAR-0310 by the end of 2024 and initiate a Phase 1a clinical trial in Q1 2025, with initial results expected in Q3 2025.
October 11, 2023 | 9:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Astria Therapeutics' licensing agreement with Ichnos Sciences for an OX40 portfolio could potentially lead to significant future revenues if the clinical trials are successful. However, the upfront payment and potential milestones represent significant costs.
The licensing agreement represents a significant investment by Astria Therapeutics, with a $15M upfront payment and up to $305M in milestones. This could potentially lead to significant future revenues if the clinical trials for STAR-0310 are successful. However, the costs associated with this agreement are significant and could impact the company's short-term financial performance.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100